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Ten patients with refractory recurrent supraventricular
tachycardia were found by electrophysiologic study to
have bypass tracts and orthodromic atrioventricular
reentrant tachycardia. All had failed to respond to con-
ventional antiarrhythmic therapy and were therefore
treated with oral amiodarone (l,600 to 2,000 mg/day for
2 weeks, then 800 to 1,200 mg/day for another 2 weeks
with subsequent 200 to 600 mg/day maintenance doses).
During or after the fourth week of therapy, electro-
physiologic study was repeated. In 9 of 10 patients,
supraventricular tachycardia could not be reinduced by
programmed stimulation. In the remaining patient, non-
sustained supraventricular tachycardia (>10 beats, last-
ing <30 seconds) with a slower basic cycle length than
that during the control period was provoked. Significant
increases in the effective refractory period of the acces-
Numerous studies (1-9) recently provided convincing evi-
dence for the marked effectiveness of the long-term admin-
istration of amiodarone in the prophylactic control of ven-
tricular and supraventricular tachyarrhythmias resistant to
conventional antiarrhythmic therapy. Rosenbaum et al. (I)
first observed that the drug might also be remarkably ef-
fective in controlling the supraventricular tachyarrhythmias
that complicate the Wolff-Parkinson-White syndrome.
However, subsequent studies (10-15) using varying dose
regimens reported variable effects on orthodromic parox-
ysmal supraventricular tachycardia. No study has utilized
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sory pathway in both the anterograde (+26%, P < 0.05)
and retrograde (+40%, p < 0.02) directions were noted,
the magnitude of change being independent of the con.
trol effective refractory period. There were also signif-
icant increases in the effective refractory period of the
right atrium (+ 24%, P < 0.01) and the right ventricle
(+ 15%, P < 0.01) during long-term therapy with
amiodarone.
Over a mean follow-up period of 20 months, symp-
tomatic control of the arrhythmia occurred in all pa-
tients; in only one patient treatment with amiodarone
could not be continued because of side effects. These
data establish the electrophysiologic basis for the effec-
tiveness of amiodarone in the prophylactic control of
refractory paroxysmal supraventricular tachycardia
complicating the bypass tract syndromes.
initial high dose treatment to attain optimal "arniodaroni-
zation" (16) before evaluating the electrophysiologic cor-
relates of long-term maintenance treatment with amiodarone
to prevent recurrences of paroxysmal supraventricular
tachycardia in previously resistant cases.
The main objectives of the present study, therefore, were
to determine the electrophysiologic effects correlating with
suppression by amiodarone of inducible supraventricular
tachycardia in previously resistant cases and to define the
role of the drug in the long-term prophylactic control of
refractory orthodromic paroxysmal supraventricular tachy-
cardia complicating accessory pathway syndromes.
Methods
Patients. Ten male patients with paroxysmal supraven-
tricular tachycardia developing in association with an ac-
cessory pathway were studied. Their ages ranged from 22
to 74 years (mean 43). The accessory pathway was left-
sided in six patients and right-sided in four, having a para-
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septal location in six and a free wall location in four (Table
1). In all cases, recurrent sustained episodes of paroxysmal
supraventricular tachycardia had been documented electro-
cardiographically; all had been refractory to one or more
antiarrhythmic drugs previously administered (Table 1). Be-
fore the electrophysiologic studies were done and amioda-
rone was administered, a complete history and physical
examination, complete blood count; serum biochemistry
profile, liver function, pulmonary and thyroid function tests,
two-dimensional echocardiogram and 12 lead electrocar-
diogram were obtained. Informed written consent was ob-
tained from all patients; the protocol for use of amiodarone
was approved by the Committee for the Use of Human
Subjects for Research in 1979.
Electrophysiologic study. After discontinuation of any
previous medication for at least 5 half-lives, the patients
underwent electrophysiologic study in the postabsorptive
nonsedated state. Endocardial electrode catheters (USCI)
were placed in the high lateral right atrium, coronary sinus,
right ventricular apex and His bundle region of the inter-
ventricular septum (17,18). Pacing was performed using a
Medtronic 5325 programmable stimulator. Recordings from
surface electrodes I, aVF, VI and endocardial electrodes in
the right atrium, coronary sinus, His bundle and the right
ventricle were obtained on an Electronics for Medicine re-
corder (VR-12). Refractory periods of the right atrium,
atrioventricular (AV) node, right ventricle and accessory
pathway were determined using single premature stimuli
(S IS2) with scanning during diastole with stimuli of increas-
ing prematurity, each delivered after an eight beat pacing
sequence (Medtronic 5325) with a cycle length (SISI) 10
to 20% above the normal sinus rate during the control pe-
riod. The same basic cycle length was then used in each
patient during amiodarone treatment. Refractory periods were
defined as previously described (18,19), and tachycardia
induction is summarized herein:
Tachycardia induction. Ventricularpacing at two or more
basic cycle lengths (S,SI), 10 to 25% above sinus cycle
length, was followed by single premature stimuli (S,S2) with
scanning during diastole until the refractory period of the
right ventricle was reached. If supraventricular tachycardia
was not produced, double premature stimuli (SIS2S3) were
delivered after two or more basic cycle lengths (SISI)' The
diastole was scarined with the double stimuli, with the short-
ening of the interval between S2 and S3 initially and then
with that between SI and S2 until both S2 and S3 approached
the right ventricular effective refractory period. If supra-
ventricular tachycardia was not induced by these measures,
rapid ventricular pacing at increasing rates was used until
retrograde ventriculoatrial (VA) block occurred or until
supraventricular tachycardia was induced.
Atrial pacing from the right atrium and coronary sinus
was then performed using the S,S2 and S,S2S3 technique in
a manner identical to that described for ventricular pacing.
Table 1. Clinical Characteristics and Location of Accessory Pathways in 10 Patients With
Orthodromic Paroxysmal Supraventricular Tachycardia
Previously
Location of Duration of Used
Age (yr) Accessory Tachycardia Antiarrhythmic
Case &Sex Pathways* (yr) Agents
26M Left-sided 15 0, PA
paraseptal
2 27M Right-sided 5 P,PA
paraseptal
3 74M Left-sided 5 D, P, °
parasepta1
4 54M Right-sided 28 PA. P, D
paraseptal
5 38M Left lateral 5 PA, P, D
wall
6 34M Right-sided 7 O,D, P
paraseptal
7 63M Left lateral 25 Q
wall
8 66M Left lateral 42 D.Q,P
wall
9 22M Right-sided 4 P, °
paraseptal
10 43M Left lateral 3 v: 0, PA
wall
Mean 43 14
*Demonstrated by electrophysiologic studies (see Table 2). D = digoxin: F = female: M = male; P =
propranolol: PA = procainamide; Q = quinidine; V = verapamil.
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If supraventricular tachycardia was not induced, rapid atrial
pacing was then undertaken at increasing rates until anter-
ograde block or supraventricular tachycardia was produced.
Atrial fibrillation was not routinely induced in our patients.
Tachycardia induction was performed during long-term
treatment with amiodarone in a manner identical to that
performed during the control study in each patient.
Location of bypass tracts. The tachycardia cycle length
and the activation sequence of the reentrant tachycardia were
determined from endocardial and surface lead recordings
obtained during pacing and supraventricular tachycardia (20).
The location of the bypass tracts was defined on the basis
of the endocardial retrograde (VA) activation sequence dur-
ing ventricular pacing and supraventricular tachycardia as
follows:
A) Left ventricular lateral wall-activation of the left
atrium first (distal coronary sinus electrode), then low right
atrium (His bundle electrode) and high right atrium.
B) Left ventricular paraseptal-low right atrium, left
atrium and high right atrium.
C) Right ventricular paraseptal-low right atrium, high
right atrium and left atrium.
Drug treatment protocol. Only patients with sustained,
inducible supraventricular tachycardia refractory to other
antiarrhythmic drugs were treated. After electrophysiologic
study, treatment was started with oral amiodarone, initially
at 1,600 to 2,000 mg (in two divided doses)/day for 2 weeks.
The dose was then decreased to 800 to 1,200 mg for another
2 weeks, at or after which time electrophysiologic study
was repeated. The dose was then decreased to 200 to 400
mg/day in all patients. In one patient, amiodarone was dis-
continued after 2 months because of fever and pulmonary
infiltrates, which resolved spontaneously on cessation of
amiodarone. During the treatment period, patients' labo-
ratory determinations were repeated at regular intervals to
assess evidence of impending toxicity, the development of
which was also monitored clinically.
Statistical analysis. Data are presented for individual
patients as well as for the study group as a whole as mean
values ± 1 standard deviation. Statistical significance of
the difference of means before and during treatment was
determined by the Student's two-tailed t test for paired data
with probability (p) < 0.05 as the limit of significance.
Results
The overall data with respect to the effects of amiodarone
on the inducibility of paroxysmal supraventricular tachy-
cardia and on the electrophysiologic variables of the heart
are summarized in Table 2 and illustrated in Figures I through
5.
Effects on inducible supraventricular tachycardia.
Before amiodarone was given, sustained supraventricular
tachycardia was inducible in all 10 patients by programmed
electrical stimulation of the heart (Table 2). During therapy
with amiodarone, supraventricular tachycardia became non-
inducible in 9 of 10 patients. In the remaining patient, one
episode of supraventricular tachycardia occurred sponta-
neously during electrophysiologic study but was not re-
producibly inducible; it was nonsustained (> 10 beats, last-
ing <30 seconds) and had a cycle length that was 130 ms
(300 versus 430 ms) longer than it was before amiodarone
was started (Fig. 1).
Effect on the refractoriness of the accessory path.
way. In all seven patients in whom the anterograde con-
duction over the accessory pathway could be demonstrated
during the control electrophysiologic study, the effective
refractory period (anterograde) was lengthened (Table 2).
In patients in whom the exact value for the effective re-
fractory period could be determined, the mean ± standard
deviation of the effective refractory period (anterograde) of
the accessory pathway was 293 ± 30 ms before amiodarone
and 368 ± 26 ms (+ 26%, P < 0.05) during amiodarone
treatment. The corresponding values for the retrograde ef-
fective refractory period of the accessory pathway before
and during amiodarone therapy were 277 ± 29 ms and 388
± 72 ms, respectively (+40%, P < 0.02).
Figure 2 illustrates the increase in the anterograde re-
fractory period of the accessory pathway plus prolongation
of conduction in the AV node and prevention of supraven-
tricular tachycardia by amiodarone. During control electro-
physiologic study anterograde block of the accessory path-
way occurs at SIS2 coupling intervals of 290 ms duration.
Anterograde conduction through the AV node then occurs
with retrograde conduction through the accessory pathway
and induction of supraventricular tachycardia. Amiodarone
increased the anterograde effective refractory period of the
accessory pathway to 390 ms (not shown) and markedly
prolonged the atrio-His conduction time (450 ms) at similar
SIS2 coupling intervals (300 ms). Retrograde conduction
through the accessory pathway is then followed by antero-
grade AV node block, thus preventing induction of supra-
ventricular tachycardia.
Figure 3 illustrates the increase in retrograde refractory
period of the accessory pathway produced by amiodarone.
During control electrophysiologic study, retrograde block
occurs at S I S2 intervals of 310 ms. The retrograde effective
refractory period of the accessory pathway is increased to
400 ms after administration of amiodarone.
Effect of amiodarone on effective refractory period
of atrium, right ventricle and AV node (Table 2).
Amiodarone increased the effective refractory period in all
the tissues. The increase in the mean effective refractory
periods was 24% (p < 0.01) in the atrium and 15% (p <
0.01) in the right ventricle. Although the anterograde ef-
fective refractory period of the AV node was increased by
amiodarone, it could not be measured in most cases because
of anterograde conduction through the accessory pathway.
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Table 2. Effects of Long-Term Amiodarone Therapy on the Electrophysiologic Variables and Inducibility of Supraventricular
Tachycardia in Patients With Accessory Pathways
Effective Refractory Period (ms) Inducibility
ofSVT at
AP Ante AP Retro RV Atria AV Node EPS
Case C A C A C A C A C A C A
I <300 340 <320 410 220 280 240 330 NA NA Yes No
2 320 380 <350 410 250 285 210 270 NA NA Yes No
3 < 240 360 <240 550 240 270 240 280 NA NA Yes No
4 NA NA 250 320 220 260 300 310 < 315 340 Yes No
5 250 370 240 500 220 240 210 280 220 300 Yes No
6 310 330 < 280 <310 210 240 210 250 240 > 330 Yes No
7 NA NA 31 0 440 250 290 250 360 NA NA Yes Yes*
8 290 390 310 400 260 280 NA NA NA NA Yes No
9 NA NA 280 350 250 270 260 300 NA NA Yes No
10 <260 <340 270 320 210 250 215 260 NA NA Yes No
Totals 293 368 277 388 233 267 237 293
± 30 ± 26 ± 29 ± 72 ± 19 ± 18 ± 30 ± 35 10
(n = 4) (n = 4) (n = 6) (n = 6) (n = 10) (n = 10) (n = 9) (n = 9)
*Nonsustained. A = during amiodarone therapy; Ante = anterograde; AP = accessory pathway; AV = atrioventricular; C = control; EPS =
electrophysiologic study; NA = not applicable or could not be done; Retro = retrograde; RV = right ventricle; SVT = supraventricular tachycardia.
An example of AV node anterograde conduction block after
treatment with amiodarone is shown in Figure 2.
Figures 4 and 5 further demonstrate the effects of amio-
darone on AV node and ventricular refractoriness and in-
duction of supraventricular tachycardia. In Figure 4, atrial
pacing with progressively premature stimuli (A\A2) produces
nondecremental conduction through the accessory pathway
(VIV2) until the effective refractoryperiod is reached. When
the effective refractory period of the accessory pathway is
reached, anterograde conduction through the AV node with
a prolonged atrio-His interval occurs. Retrograde conduc-
tion through the accessory pathway results in induction of
supraventricular tachycardia. Amiodarone prolongs the an-
terograde AV node refractory period to an extent where AV
node block occurs before the anterograde effective refrac-
tory period of the accessory pathway is reached, thus pre-
venting the induction of supraventricular tachycardia. The
anterograde effective refractory period of the accessory
pathway is also increased. During ventricular pacing (Fig.
5), amiodarone prolongs the functional refractory period of
the right ventricle to a point outside the tachycardia zone
noted during controlelectrophysiologicstudy in this patient,
thus preventing the induction of supraventricular tachycardia.
Long-term clinical outcome and drug side effects. In
9 of 10 patients, the recurrence of spontaneous supraven-
tricular tachycardia was suppressed 100% after the first month
of amiodarone therapy over a mean duration of therapy of
20 months (range 10 to 29). In one patient, amiodarone had
to be discontinued after 2 months of therapy because of the
onset of fever, pulmonary infiltrates and elevated serum
levels of hepatic enzymes. The nine patients remaining on
long-term therapy (200 to 400 mg/day) have been free of
clinically significant side effects.
Discussion
The reentrant nature of orthodromic paroxysmal supra-
ventricular tachycardia in patients with accessory pathways
is now well defined (20-22) . The reentrant circuit incor-
porates the atrioventricular (AV) node and His bundle (and
branches) as the anterograde limb and the anomalous tract
as the retrograde limb, while atrial and ventricular tissues
provide the final proximal and distal common pathways for
the initiation and perpetuation of the tachycardia. Thus, the
rational approach for its control is to prolong refractoriness
or conduction, or both, in one or more components of the
entire reentrant circuit or to eliminate the trigger mechanism
(for example, ventricular or supraventricular extrasystoles)
initiating the arrhythmia. Different antiarrhythmic com-
pounds have been shown to exhibit variable potencies in
this regard (23- 29).
Inconsistency in amiodarone's effects on supraven-
tricular tachycardia. In the case of amiodarone, the suc-
cess rate varying between 33 and 100% (1,3 , 10- 15) is note-
worthy because the electrophysiologic properties of thedrug
during long-term administration are reasonably uniform (5,7).
It lengthens repolarization and effective refractoryperiod in
all cardiac tissue (5,7,30,31). One might, therefore, expect
a greater consistency in the overall therapeutic effects of
amiodarone in orthodromic paroxysmal supraventricular
tachycardia than has been reported (10,12, 13- 15).
Present study . Our results show that when the drug is
given orally for at least 4 weeks (in our patients at a high
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Figure 1. Case 7. Effect of long-term
amiodarone administration on the in-
ducibility of supraventricular tachy-
cardia in a patient with a bypass tract
subject to recurrent orthodromic par-
oxysmal supraventricular tachycardia.
Upper panel, Induction of supraven-
tricular tachycardia by atrial pacing
before amiodarone was started. Lower
panel, Spontaneous supraventricular
tachycardia occurs during electro-
physiologic study after two premature
ventricular complexes. With amioda-
rone, the supraventricular tachycardia
was nonsustained with a tachycardia
cycle length longer than that under
control conditions. The tachycardia
could not be reinduced by pacing. I,
AYF, Y I = surface electrocardio-
graphic leads; A = atrial deflection;
Ae = retrograde deflection; DCS =
distal coronary sinus electrogram; H
or HBE = His deflection or His bun-
dle electrogram, respectively;HRA =
high right atrial electrogram; PCS =
proximal coronary sinus electrogram;
S = stimulus; Y = ventricular
deflection.
'.-c • .. - ... =' =
loading dosage), it leads to a significant increase in the
effective refractory period of the atria, AV node, ventricle
and accessory pathways (anterograde and retrograde). In
our 10 patients, this was associated with the near complete
suppression of the tendency for electrically inducible supra-
ventricular tachycardia. Furthermore, over a mean follow-
up period of 20 months on maintenance doses (200 to 400
m/day), the drug was uniformly effective in eliminating
recurrences of paroxysmal supraventricular tachycardia, with
side effects occurring in only one patient.
Previous studies. Such a response is in line with the less
standardized approach to dosage regimen used by Rosen-
baum et al. (I) and others (3,32). Of particular significance
is the preliminary report by Rasmussen and Berning (II),
who found amiodarone-induced increases in the refractory
period in the atrium, AV node and accessory pathway as a
function of duration of treatment in six patients with in-
ducible supraventricular tachycardia. Their initial dose of
amiodarone was 600 mg/day for 10 to 14 days, followed
by 400 mg/day until the appropriate response had been ob-
tained, after which the dose was reduced to 250 to 400
mg/day. They repeated electrophysiologic study in four such
patients after 26 to 85 days of treatment; induction of supra-
ventricular tachycardia was prevented in all four patients.
These data, which are comparable with our own, are in
contrast to those of Wellens et al. (10), who found that
amiodarone prevented inducible supraventricular tachy-
cardia in only 5 of 15 patients. Nevertheless, the drug in-
variably prolonged the tachycardia cycle length in those in
whom it was reinducible. As in our study, Wellens et al.
(10) noted a marked increase in the effective refractory
period of the accessory pathway in the anterograde direction;
however, they found a less striking effect on this variable
in the retrograde direction. By contrast, we found a greater
increase in the effective refractory period in the retrograde
(40%) than in the anterograde (26%) direction, in addition
to the somewhat larger increase in the right ventricular ef-
fective refractory period (about 34 ms) than that (23 ms)
reported by Wellens et al. (10).
Dosage regimen and duration of therapy. The differ-
ences between our data and those of Rasmussen and Berning
(II) and Wellens et ai. (10) may be due to the differing
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Figure 2. Case 8. Changes in atrioven-
tricular (AV) conduction and tachycardia
induction before and after long-term
arniodarone therapy in another patient with
a bypass tract. Upper panel, Control re-
cordings during atrial stimulation dem-
onstrating ventricular pre-excitation.
Middle panel, Control recordings show-
ing the anterograde effective refractory
period of the accessory pathway during
atrial premature stimulation, anterograde
conduction through the AV node and in-
duction of supraventricular tachycardia.
Lower panel, Note that amiodarone
lengthened the anterograde effective re-
fractory period of the accessory pathway
and AV conduction, thus preventing in-
duction of supraventricular tachycardia by
anterograde AV node block. RV = right
ventricular electrogram; other abbrevia-
tions as in Figure I.
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Figure 3. Case 8. An example of the
prolongation of the retrograde effec-
tive refractory period of the accessory
pathway induced by long-term admin-
istration of oral amiodarone. Upper
and middle panels, Control record-
ings during right ventricular pacing
demonstrating accessory pathway
conduction and the effective refractory
period (310 ms). Lower panel, Re-
cordings during amiodarone treat-
ment. The drug markedly lengthened
the effective refractory period (400 ms)
of the accessory pathway. Abbrevia-
tions as in Figure I.
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Figure 4. Case6. Datafrom electrophysiologic study before and
during amiodarone treatment showing anterograde nondecrementaI
conduction through theaccessory pathway during atrial premature
stimulation. When the effective refractory period of the accessory
pathway is reached (a), anterograde conduction through the atrio-
ventricular node with prolonged atrio-His interval occurs and in-
duces reentrant supraventricular tachycardia (SVT). Amiodarone
prolongs anterograde AV nodeconduction and accessory pathway
effective refractory period to a point outside the tachycardia zone
(b), thus preventing induction of supraventricular tachycardia. A)A2
= atrial intervals; VIV2 = ventricular intervals.
dosage regimens used. Adequate' 'amiodaronization' in our
patients and in the study by Rasmussen and Berning (11)
was achieved by higher initial loading doses and by a longer
duration of therapy before electrophysiologic reevaluation
was undertaken; Wellens et al. (10) utilized 600 mg/day of
amiodarone for 7 days followed by 300 mg/day for another
7 days, at which time repeat electrophysiologic study was
performed .
The elimination half-life of chronically administered
amiodarone is exceedingly long and variable (33) and ad-
equate amiodaronization is thus a function not only of dose,
but also of duration of therapy. Thus, it is unlikely that a
steady state drug therapy had been achieved in the patients
studied by Wellens et al. (10). Nevertheless, their data are
directionally similar to those from our laboratory as well as
to those reported by Rasmussen and Berning (II ); they
provide convincing evidence for the high degree of effec-
tiveness of amiodarone in the prophylactic control of or-
thodromic supraventricular tachycardia in patients with by-
pass tracts. However, they do not indicate the precise
mechanisms to account for the extraordinary efficacy of the
drug in this context. A comparison of the cardiac electro-
physiologic actions of various antiarrhythmic drugs relative
to their clinical efficacy in orthodromic paroxysmal supra-
~oo (j)
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460 B
440 B
4 20 B
tl 400 aN
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Figure 5. Case 6. Datafrom electrophysiologic study before and
during amiodarone therapy showing retrograde nondecremental
conduction through the accessory pathway during ventricular pre-
mature stimulation. A defined tachycardia zone is noted in this
patient during the control study. After amiodarone therapy, the
ventricular functional refractory period is prolonged to a point
outside the tachycardia zone, thus preventing induction of supra-
ventricular tachycardia. A1cA2c = retrograde A intervals; other
abbreviations as in Figure 4.
ventricular tachycardia might indicate the potential mech-
anisms involved.
Comparison with other agents. Numerous agents have
been studied with respect to their electrophysiologic effects
and efficacy in suppressing inducible supraventricular tachy-
cardia in the Wolff-Parkinson-White syndrome. The fre-
quency of suppression of inducible tachycardia after intra-
venous administration was 50% with quinidine and ajmaline
(23), 75% with procainamide (23) and 70% with disopyr-
amide (26,27). These class I agents acted primarily by in-
creasing refractoriness in the accessory pathway and block-
ing the retrograde limb of the reentrant circuit, with little
effect on the AV node or anterograde limb (23,26,27). By
contrast, intravenous ouabain , propranolol and verapamil
were effective in approximately 50% of patients (24,29) and
affected primarily AV node refractoriness (anterograde limb)
with no effect on accessory pathway refractoriness .
Of particular significance are the data from four patients
with orthodromic paroxysmal supraventricular tachycardia
studied by Reid et al. (25) after intravenous administration
of aprindine . In all four patients, induction of supraven-
tricular tachycardia was prevented by the drug which, like
amiodarone in our study, increased the effective refractory
period in the AV node and bypass tracts in addition to those
in the atria and ventricles. Thus, the data suggest that in
orthodromic paroxysmal supraventricular tachycardia, ef-
ficacy of an agent may be dependent on the degree of length-
ening of the effective refractory period in the AV node
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(anterograde) as well as in the bypass tracts (retrograde).
For this reason, compared with that of amiodarone or aprin-
dine, a lower rate of efficacy in orthodromic paroxysmal
supraventricular tachycardia might be expected for agents
with a narrower spectrum of electrophysiologic effects (for
example, class I agents, digoxin, propranolol and verapamil).
Mechanisms of action. In our study, amiodarone was
shown to prevent induction of supraventricular tachycardia
by several potential mechanisms. These included prolon-
gation of refractory periods and block of anterograde con-
duction in the AV node and retrograde conduction in the
accessory pathway and, in one case, prolongation of the
refractory period of the right ventricle to a point outside the
tachycardia zone. The possibility must also be considered
that in paroxysmal supraventricular tachycardia, the drug
additionally might act by the reduction of premature atrial
and ventricular complexes that provide the trigger mecha-
nism for the initiation of the tachycardia (34). At least for
premature ventricular complexes, amiodarone has been shown
to be a powerful suppressant (4,5,16).
Implications. Orally administered amiodarone appears
to be extremely effective in suppressing inducible sustained
supraventricular tachycardia in the Wolff-Parkinson-White
syndrome. The incidence of side effects with the patient
receiving the minimal dose required to suppress sponta-
neously recurring paroxysmal supraventricular tachycardia
(generally 200 to 400 mg/day) over a 20 month follow-up
period was found to be low. The data suggest that the high
rate of prophylactic efficacy of amiodarone in orthodromic
paroxysmal supraventricular tachycardia may relate to the
significant increases in the effective refractory period of the
various components of the reentrant circuit, especially the
AV node and the bypass tracts.
We are much indebted to Alma Gump and Lacy Goede for typing this
manuscript. We are also grateful to 10Ann Hendrickson and the technical
staff of Electrophysiologic Laboratories at the Veterans Administration
Medical Center, West Los Angeles and the Center for Health Sciences at
the University of California at Los Angeles, California for their assistance
in the studies.
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